Clinical Trials
66 trialsNCT01742299 2026-05-14
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Novartis
Phase 4 Completed
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT02352558 2023-11-14
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT01593254 2023-06-22
DASCERN
Bristol-Myers Squibb
Phase 2 Completed
NCT00171223 2021-07-22
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
Novartis
Phase 2 Completed
NCT00171249 2021-07-22
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Novartis
Phase 2 Completed
NCT00171158 2021-06-25
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
Novartis
Phase 2 Completed
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT03454503 2021-02-23
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
Hikma Pharmaceuticals LLC
Completed
NCT01468688 2020-12-21
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Novartis
Phase 1 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT00510354 2020-09-10
Radix
Novartis
Phase 4 Completed
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT00574873 2019-01-08
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Pfizer
Phase 3 Completed
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT01316458 2017-06-01
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Novartis
Phase 2 Completed
NCT01172548 2017-05-31
INV555
Novartis
Phase 2 Completed
NCT00150072 2017-02-23
Efficacy and Safety of Imatinib in Chordoma
Novartis
Phase 2 Completed
NCT00171899 2017-02-23
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
Novartis
Phase 4 Completed
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT00481247 2017-02-15
DASISION
Bristol-Myers Squibb
Phase 3 Completed
NCT00372476 2017-02-07
INV181
Novartis
Phase 4 Completed
NCT02977312 2016-11-30
CCMLJ
Hikma Pharmaceuticals LLC
Completed
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT01483014 2016-11-18
CONVERT
Novartis
Phase 2 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT01188278 2016-09-30
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
Bristol-Myers Squibb
Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT00428909 2016-04-21
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 1 Completed
NCT01275196 2016-04-08
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
Novartis
Phase 3 Completed
NCT00420043 2016-04-05
Effect of Food on Bioavailability of Modified Release Formulations of Imatinib
Novartis
Phase 1 Completed
NCT00422825 2016-04-05
Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib
Novartis
Phase 1 Completed
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed
NCT00982488 2016-01-22
START rollover
Bristol-Myers Squibb
Phase 2 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT01795716 2015-05-19
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT01751919 2014-10-01
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
Dong-A ST Co., Ltd.
Phase 1 Completed
NCT00237185 2014-08-19
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Phase 2 Completed
NCT02103322 2014-06-27
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
Amneal Pharmaceuticals, LLC
Phase 2/3 Completed
NCT00006052 2014-01-31
STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
Novartis
Phase 2 Completed